Exelon, for example, is a treatment for Alzheimer’s that helps patients cope with the disease and remain independent longer. Marketed by Novartis, the drug is based on research that was conducted at Hebrew University. Doxil, sold by Johnson and Johnson, effectively helps treat numerous cancers, and it, too, was developed at Hebrew U, along with researchers at Hadassah Medical Center. And, of course, there’s multiple sclerosis drug Copaxone, developed at the Weizmann Institute and marketed by Israel’s own Teva Pharmaceuticals.
Melodea develops environmentally-friendly, nano-crystalline cellulose based products from side streams of the paper industry
Using viruses from Jerusalem's sewage system, Hebrew University-Hadassah School of Dental Medicine researchers have developed an innovative treatment against dental bacteria that are resistant to growing numbers of antibiotics.
The team developed bacteriophage (“phages”) viruses to gobble up enterococcus bacteria that are resistant to a wide variety of antibiotics that is described by health authorities around the world as a major danger to health.
Capital to be used for completion of on-going Phase 2b study of ladostigil, for treatment of mild cognitive impairment, and preparations for pivotal Phase 3 trial
Eight start ups created in 2015 only!
New fiber optic guide-wire will enable surgeons to perform highly accurate hip fracture and spinal fusion surgery with minimal side effects
Troublemaking’ bacteria that is a major factor in periodontitis prevents the body from properly fending off cancerous cells, Hebrew U research shows
A saliva-based pregnancy test, a blood test to predict severe health issues, and a home printer which produces complex electronic equipment.
It sounds like science fiction, but for Israeli inventors and their clients, it is an achievable to-do list for the next two years.
Yaacov Michlin, chief executive of the Hebrew University's technology transfer arm Yissum, is responsible for helping researchers turn these innovative ideas into marketable products.
In terms of the outcomes Yissum can create from limited resources, Mr Michlin said the organisation was in the top five of its kind globally, and the largest and most active such company in Israel.
As a young physics student in the Soviet Union, Prof. Alexander Vainstein never could have imagined that one day he’d be helping people with malaria, but that’s exactly what happened – and all thanks to some colorful flowers.
In her bid for the Democratic nomination, Clinton rarely misses an opportunity to tout her record on early childhood education, from her first job out of law school at the Children’s Defense Fund to her Too Small To Fail program at The Clinton Foundation.
Never far down on her list is the Home Instruction for Parents of Preschool Youngsters, the program she imported to Arkansas from Israel. HIPPY trains parents — mostly women — in low-income communities to teach their young children basic skills, like counting or shape recognition, reflecting the ethos that parents are their children’s first teachers.
The Ripples technology originated at Prof. Shlomo Magdassi’s lab at the Hebrew University of Jerusalem, was licensed-out by Yissum, the technology transfer company of the Hebrew University, and was brought to market with seed funding from Landa Ventures.
HumanEyes was founded by Yissum and Professor Shmuel Peleg, from the School of Engineering and Computer Science of The Hebrew University of Jerusalem.
CollPlant is a clinical stage regenerative Medicine Company focused on developing and commercializing tissue repair products, initially for orthobiologics and advanced wound care markets. Our products are based on our rhCollagen (recombinant human collagen) that is produced with CollPlant’s proprietary plant based genetic engineering technology.
Yissum's start up Betalin Therapeutics is developing an engineered micro-pancreas (EMP) that can sustain significant levels of glucose-regulated insulin secretion from transplanted beta cells.
They are at the heart of every electronic device. Yet the way printed circuit boards, or PCBs, are made, hasn't changed in decades. Enter Israeli startup Nano Dimension. It's looking to disrupt this 100 billion-dollar market with an all-new 3D printer.
Enter AB103, a rationally designed short peptide that modulates the inflammatory response by binding to the CD28 dimer interface. Ness Ziona, Israel-based Atox has just launched the phase III study called ACCUTE, a rough acronym for "AB103 Clinical Composite endpoint StUdy in necrotizing soft Tissue InfEctions." Conducted at 40 centers in the U.S., the experiment will enroll 290 patients given round-the-clock support and treatment. Data should be available by the end of 2017.
Within the next 24 months, the Israeli company NanoLock expects to win regulatory clearance for its first two products embedded with a novel antimicrobial nanomaterial developed in the lab of Prof. Ervin Weiss, former head of prosthodontics at the Hebrew University Hadassah School of Dental Medicine in Jerusalem and current dean of the Tel Aviv University dental school.Within the next 24 months, the Israeli company NanoLock expects to win regulatory clearance for its first two products embedded with a novel antimicrobial nanomaterial developed in the lab of Prof. Ervin Weiss, former head of prosthodontics at the Hebrew University Hadassah School of Dental Medicine in Jerusalem and current dean of the Tel Aviv University dental school.
YIssum's startup Betaline Therapeutics is currently in pre clinical studies.
Yissum's startup Briefcam creates video synopsis of important events of survailance camera footage.
Betalin Therapeutics strives to cure diabetes by a single transplant of its proprietary Engineered Micro Pancreas (EMP), that provides significant levels of glucose-regulated insulin secretion over extended periods of time. The company was established in 2015, based on technology developed at the lab of Prof. Eduardo Mitrani from Department of Cell and Developmental Biology at the Hebrew University of Jerusalem and was licensed under an exclusive worldwide agreement with Yissum, the technology transfer office of the Hebrew University.